Immunai
PrivateLast Round
Series B
Oct 27, 2021
Est. Valuation
$1B
Total Funding Raised
$295M
Company Overview
Immunai is a biotechnology company that leverages artificial intelligence and single-cell genomics to map the immune system for the development of targeted immunomodulatory therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Revenue Share
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunai Comparables
Compare Immunai with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Insitro | 84% | |
| Owkin | 83% | |
| IMU Biosciences | 81% | |
Immunai Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 27, 2021 | ||||
| Series A | Feb 11, 2021 | ||||
| Seed | May 14, 2020 |
Key People
Founding team and executive leadership
Immunai Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ICON | Series B |
| Duquesne Family Office | Series A |
| Koch-ventures.com | Series B |
| Gefen Capital | Series B, Series A |
| Charles and Lynn Schusterman Family Philanthropies | Series A |
| Schusterman Family Investments | Series A |
| Catalio Capital Management | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 15, 2026
Partnered with Bristol Myers Squibb on a strategic collaboration.
- Jan 12, 2026
Developing an AI model of the immune system called the IDE(TM) engine.
Immunai Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Immunai's valuation, stock price, and market status.